



## Ocular Therapeutix™ to Report Third Quarter 2017 Financial Results

October 31, 2017

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 31, 2017-- Ocular Therapeutix™, Inc.(NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter 2017 financial results on Tuesday, November 7, 2017. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's financial results and provide a general business update.

The live webcast can be accessed by visiting the Investors section of the Company's website at [investors.ocutx.com](http://investors.ocutx.com). Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765) 507-2620 (International) to listen to the live conference call. The conference ID number for the live call will be 7468418. An archive of the webcast will be available until November 21, 2017 on the Company's website.

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171031005517/en/>

Source: Ocular Therapeutix, Inc.

### Investors

Burns McClellan  
Steve Klass, 212-213-0006  
[sklass@burnsmc.com](mailto:sklass@burnsmc.com)

or

Ocular Therapeutix  
Donald Notman  
Chief Financial Officer  
[dnotman@ocutx.com](mailto:dnotman@ocutx.com)

or

### Media

Ocular Therapeutix  
Scott Corning  
Vice President of Marketing & Commercial Operations  
[scorning@ocutx.com](mailto:scorning@ocutx.com)